胶质纤维酸性蛋白及基因多态性与首发精神分裂症的相关性研究

发布时间：2018-05-28 16:11

本文选题：首发精神分裂症 + 胶质纤维酸性蛋白　；参考：《昆明医科大学》2013年硕士论文

【摘要】：目的探讨首发精神分裂症患者血清胶质纤维酸性蛋白(GFAP)浓度及其基因SNPrs2070935多态性与疾病的关联方法我们对门诊收集的58例首发精神分裂症的患者,及来自健康体检的52例年龄、性别匹配的正常对照进行研究。完成自制一般情况调查问卷及PANSS以评估病情程度。采用酶联免疫吸附剂法(enzyme linked immunosorbent assay, ELISA)测定血清GFAP浓度,采用聚合酶链式反应(Polymerase Chain Reaction, PCR)扩增目的片段,测定PCR产物的DNA序列,进行序列比对后判定GFAP基因SNPrs2070935基因型。采用t检验、χ2检验、方差分析及Spearman相关分析进行数据统计分析。结果(1)首发精神分裂症患者血清GFAP浓度高于对照组(4.21±0.72ng/Lvs3.33±0.85ng/L, t=5.90, P0.01),分别与不同性别、年龄、]PANSS得分等因素进行分析,结果显示血清GFAP浓度与在这些因素中的差异无统计学意义；(2)总样本三种基因型的构成比：CC型(56.36%)、CA型(34.55%)、AA型(9.09%)；病例组构成比分别为44.83%、41.38%、13.79%；对照组为69.23%、26.92%、3.85%,病例组与对照组间基因型的分布具有统计学差异(χ2=7.54,P=0.023),同时等位基因频率分布也具有统计学差异(χ2=8.33,P=0.004)；.(3)三种基因型的血清GFAP浓度无统计学差异(F=0.85,P=0.43),病例组与对照组不同基因型的血清GFAP浓度也无统计学差异(F值分别为0.73和0.07,P值分别为0.69和0.94)。结论病例组的血清GFAP浓度高于对照组,而GFAP基因多态性与血清GFAP浓度无相关性,表明首发精神分裂症患者存在神经胶质细胞损害,推测是在反馈性保护机制下,GFAP参与了神经胶质细胞损伤后的修复与再生。而血清GFAP浓度改变与基因突变无关,可能与其他多种因素的参与有关；另研究结果显示人群GFAP基因的突变与精神分裂症发病存在一定的关联,表明这一突变基因在精神分裂症的发病中可能是一个潜在的危险因子。
[Abstract]:Objective to investigate the association between serum glial fibrillary acidic protein (GFAP) concentration, gene SNPrs2070935 polymorphism and disease in patients with first-episode schizophrenia. Methods We studied 58 first-episode schizophrenia patients and 52 age-matched healthy controls. Self-made general situation questionnaire and PANSS were completed to assess the severity of the disease. Enzyme linked immunosorbent assay (Elisa) was used to detect the concentration of GFAP in serum, and polymerase chain reaction (PCR) was used to amplify the DNA sequence of PCR product. The SNPrs2070935 genotype of GFAP gene was identified after sequence alignment. T test, 蠂 2 test, ANOVA and Spearman correlation analysis were used to analyze the data. Results (1) the serum GFAP concentration in the first episode schizophrenic patients was higher than that in the control group (4.21 卤0.85ng / L, t = 5.90, P 0.01g / L, respectively). The results were analyzed with sex, age,] PANSS score and so on. The results showed that there was no significant difference between the serum GFAP concentration and these factors. (2) the composition of the three genotypes in the total sample was higher than that in the total sample: the composition of the three genotypes in the total sample was higher than that in the control group (69.23%, 26.922%, 3.85%, in the control group, 69.23%, 26.922%, 3.85%, in the control group, and in the control group, respectively, the ratio was 44.8333.38 13.79). There was no statistical difference in the distribution of serum GFAP among the three genotypes (蠂 ~ 2 ~ (7.54) (蠂 ~ (2) = 7.54) and allele frequency (蠂 ~ (2) = 8.33). There was no significant difference in serum GFAP concentration among the three genotypes. The serum GFAP concentration of different genotypes in the case group and the control group was no significant difference, and there was no significant difference in the serum GFAP concentration between the patients and the control group. The F values were 0.73 and 0.07, P values were 0.69 and 0.94 respectively. Conclusion the concentration of serum GFAP in the case group is higher than that in the control group, but there is no correlation between the GFAP gene polymorphism and the serum GFAP concentration, which indicates that there is glial cell damage in the patients with first-episode schizophrenia. It is speculated that GFAP is involved in the repair and regeneration of glial cells after injury under the feedback protection mechanism. However, the change of serum GFAP concentration is not related to gene mutation, but may be related to many other factors. The results also show that the mutation of GFAP gene is associated with the onset of schizophrenia. These results suggest that this mutation gene may be a potential risk factor in the pathogenesis of schizophrenia.
【学位授予单位】：昆明医科大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R749.3

【参考文献】